Details for Patent: 6,326,367
✉ Email this page to a colleague
Title: | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Abstract: | The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: ##STR1## |
Inventor(s): | Miller; Chris P. (Strafford, PA), Collini; Michael D. (Clifton Heights, PA), Tran; Bach D. (Media, PA), Santilli; Arthur A. (Havertown, PA) |
Assignee: | American Home Products Corporation (Maidson, NJ) |
Filing Date: | Sep 02, 1999 |
Application Number: | 09/388,581 |
Claims: | 1. A method of treatment of ovarian cancer in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound selected from the formulas I or II: ##STR189## wherein: R.sub.1 is selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 alkyl (straight chain or branched), --O--C.sub.1 -C.sub.12 alkyl (straight chain or branched or cyclic), or halogens; or C.sub.1 -C.sub.4 halogenated ethers; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 (straight chain or branched), --O--C.sub.1 -C.sub.12 (straight chain or branched or cyclic), halogens, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH; X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen; n is 2 or 3; Y is the moiety: ##STR190## wherein: a) R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or b) R.sub.7 and R.sub.8 are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN--, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or c) R.sub.7 and R.sub.8 are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or d) R.sub.7 and R.sub.8 are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or e) R.sub.7 and R.sub.8 are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or f) R.sub.7 and R.sub.8 are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4) alkyl; or a pharmaceutically acceptable salt thereof. 2. A method of claim 1 wherein: R.sub.1 is selected from H, OH, --O--C(O)--C.sub.1 -C.sub.4 alkyl or --O--C.sub.1 -C.sub.4 alkyl, halogen; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, cyano, C.sub.1 -C.sub.6 alkyl, or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH; X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, triflouromethyl, halogen; Y is the moiety, ##STR191## R.sub.7 and R.sub.8 are selected independently from H, C.sub.1 -C.sub.6 alkyl, or combined by --(CH.sub.2)p-, wherein p is an integer of from 2 to 6, so as to form a saturated ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONH(C.sub.1 -C.sub.4), --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, di(C.sub.1 -C.sub.4)alkylamino, --NHSO.sub.2 (C.sub.1 -C.sub.4), --NHCO(C.sub.1 -C.sub.4), or --NO.sub.2 ; or a pharmaceutically acceptable salt thereof. 3. A method of claim 1 wherein the compound is selected from the formulas I or II: ##STR192## wherein: R.sub.1 is selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 alkyl (straight chain or branched), --O--C.sub.1 -C.sub.12 alkyl (straight chain or branched or cyclic), or halogens; or C.sub.1 -C.sub.4 halogenated ethers; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 (straight chain or branched), --O--C.sub.1 -C.sub.12 (straight chain or branched or cyclic), halogens, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH; X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen; n is 2 or 3; Y is the moiety: ##STR193## wherein: a) R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or b) R.sub.7 and R.sub.8 are concatenated to form a pyrrolidine ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN--, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or c) R.sub.7 and R.sub.8 are concatenated to form a piperidine ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or d) R.sub.7 and R.sub.8 are concatenated to form an azepan ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or e) R.sub.7 and R.sub.8 are concatenated to form a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or a pharmaceutically acceptable salt thereof. 4. A method of claim 1 wherein the compound is selected from the formulas I or II: ##STR194## wherein: R.sub.1 is selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH; X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen; n is 2 or 3; Y is the moiety: ##STR195## wherein R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or R.sub.7 and R.sub.8 are concatenated to form a nitrogen containing heterocyclic moiety selected from the group of: ##STR196## the nitrogen containing heterocyclic moiety being optionally substituted by from 1 to 3 groups selected from hydrogen, hydroxy, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, --CN, --CO.sub.2 H, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2 or --NO.sub.2 ; or a pharmaceutically acceptable salt thereof. 5. A method of claim 4 wherein R.sub.1 is selected from X, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers; R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH; X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen; n is 2 or 3; Y is the moiety: ##STR197## wherein R.sub.7 and R.sub.8 are independently selected from the group of H or C.sub.1 -C.sub.6 alkyl; or R.sub.7 and R.sub.8 are concatenated to form a nitrogen containing heterocyclic moiety of the group: ##STR198## the nitrogen containing heterocyclic moiety being optionally substituted by from 1 to 3 groups selected from hydrogen, hydroxy, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, --CN, --CO.sub.2 H, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2 or --NO.sub.2 ; or a pharmaceutically acceptable salt thereof. 6. A method of claim 1 wherein the compound is selected from the group of: 5-Benzyloxy-2-(4-ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben zyl]-1H-indole; 5-Benzyloxy-2-phenyl-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1H-indole ; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-ben zyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-diisopropylamino-1-yl-e thoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-butyl-methylamino-1-yle thoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl-1-{4-dimethylamino)-ethoxy]-benz yl}-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piperidin-1-y l)-ethoxy]-benzyl}-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piperidin-1-y l)-ethoxy]-benzyl}-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(4-methyl-piperidin-1-y l)-ethoxy]-benzyl}-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1{4-[2-((cis)-2,6-Dimethyl-pipe ridin-1-yl)-ethoxy]-benzyl}-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-{4-[2-(1,3,3-trimethyl-6-aza-bi cyclo[3.2.1]oct-6-yl)-ethoxy]-benzyl}-1H-indole; (1S,4R)-5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl{4-[2-(2-Aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy]-benzyl}-1H-indole; 5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-benzyl ]-1H-indole; 5-Benzyloxy-2-(4-flouro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben zyl]-1H-indole; 5-Benzyloxy-2-(4chloro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benz yl]-1H-indole; 5-Benzyloxy-2-[3,4-methylenedioxy-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-e thoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-[4-isopropoxy-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy) -benzyl]-1H-indole; 5-Benzyloxy-2-[4-methyl-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben zyl]-1H-indole; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-benzyloxy-phenyl)-3-me thyl-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl -ethoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-et hoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(3-methoxy-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-3-me thyl-1H-indole; 5-Benzyloxy-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluorom ethoxy-phenyl)-1H-indole; (2-{4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenox y}-ethyl)-cyclohexyl-amine; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-methylpiperazin-1-yl)-etho xy]-benzyl}-1H-indole; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-methoxy-phenyl)-3-meth yl-1H-indole; 4-{3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indole; 4-{3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl)-phenol hydrochloride; 3-Methyl-2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl]-1H-indol-5-ol; 4-{5-Methoxy-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benzyl}-1H-indol-2-y l}-phenol; 2-(4-methoxy-phenyl)-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benzyl}-1H-i ndol-5-ol; 5-Methoxy-2-(4-methoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benz yl]-1H-indole; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-methoxy-2-(4-methoxy-phenyl)-3-methyl -1H-indole; 2-(4-Ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-ethoxy-phenyl)-3-methyl-1H-indol-5 -ol; 4-{5-Fluoro-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl}- phenol; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-3-methyl-2-phenyl-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-pyrollidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol; 1-[4-(2-Azocan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol- 5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-dimethyl-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-diethyl-1-yl-ethoxy)-benzyl]-1H-indol -5-ol; 1-[4-(2-Dipropylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indo l-5-ol; 1-[4-(2-Dibutylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol; 1-[4-(2-Diisopropylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-i ndol-5-ol; 1-{4-[2-(Butyl-methyl-amino)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl)-3-methyl- 1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piperidin-1-yl)-ethoxy]-ben zyl}-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piperdin-1-yl)-ethoxy]-benz yl}-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(4methyl-piperidin-1-yl)-ethoxy]-benz yl}-1H-indol-5-ol; 1-{4-[2-(3,3-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl)- 3-methyl-1H-indol-5-ol; 1-{4-[2-((cis)-2,6-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hydroxy-ph enyl)-3-methyl-H-indol-5-ol; 2-(4-Hydroxy-phenyl)-1-{4-[2-(4-hydroxy-piperidin-1-yl)-ethoxy]-benzyl}-3-m ethyl-1H-indol-5-ol; (1S,4R)-1-{4-[2-(2-Aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicyclo[3.2. 1]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol; 2-(4-Fluoro-phenyl)-3-methyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-fluoro-phenyl)-3-methyl-1H-indol-5 -ol; 2-(3-Methoxy-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benz yl]-1H-indol-5-ol; 2-Benzo[1,3]dioxol-5-yl-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H- indol-5-ol; 2-(4-Isopropoxy-phenyl)-3-methyl-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-isopropoxy-phenyl)-3-methyl-1H-ind ol-5-ol; 2-(4-Cyclopenyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]- 1H-indol-5-ol; 3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-4-trifluoromethyl-phen yl)-1H-indol-5-ol; 3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-p-tolyl-1H-indol-5-ol; 2-(4-Chloro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol; 2-(2,4-Dimethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H -indol-5-ol; 2-(3-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(3-hydroxy-phenyl)-3-methyl-1H-indole -5-ol; 2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzy l]-1H-indol-5-ol; 2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(azepan-1-yl-ethoxy)-benzyl]-1H -indol-5-ol; 2-(3-Methoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ole-5-ol; 3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluoromethoxy-pheny l)-1H-indole-5-ol; 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol; 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol; 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1H-indol- 5-ol; 3-Chloro-2-(4-hydroxy-2-methyl-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzy l]-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-3-ethyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol; 5-Hydroxy-2-(4-Hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dole-3-carbonitrile; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-hydroxy-2-(4-hydroxy-phenyl)-1H-indol e-3-carbonitrile; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperidin-1-yl-ethoxy)- benzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-azepan-1-yl-ethoxy)-ben zyl]-1H-indole; 5-Benzyloxy-2-(2-methyl-4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperidin-1-yl -ethoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-ethyl-1-[4-(2-piperidin-1-yl-ethoxy)-b enzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-piperidin-1-yl-ethoxy)-b enzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-azepan-1-yl-ethoxy)-benz yl]-1H-indole; Di-propionate of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol; Di-pivalate of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-[4-(3-piperidin-1-yl-propoxy)-benzyl]- 3-methyl-1H-indole; 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[3-(piperidin-1-yl)-propoxy]-benzyl}-1H- indol-5-ol; 2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-piperidin-1-yl-ethoxy)-benzyl]-3-met hyl-1H-indol-5-ol; 2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-azepan-1-yl-ethoxy)-benzyl]-3-methyl -1H-indol-5-ol; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[3-Methoxy-4-(2-piperidin-1-y l-ethoxy)-benzyl]-1H-indole; 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[2-Methoxy-4-(2-azepan-1-yl-e thoxy)-benzyl]-1H-indole; Di-pivalate ester of 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol; 5-Benzyloxy-2-(4benzyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-b enzyl]-1H-indole; 5-Benzyloxy-2-(3-benzyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)- benzyl]-1H-indole; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol methiodide; 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-dimethyl-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol methiodide; or a pharmaceutically acceptable salt thereof. 7. A method of treating ovarian cancer in a mammal, the method comprising administering to the mammal in need thereof a pharmaceutically effective amount of 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol, or a pharmaceutically acceptable salt thereof. 8. A method of treating ovarian cancer in a mammal, the method comprising administering to the mammal in need thereof a pharmaceutically effective amount of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol, or a pharmaceutically acceptable salt thereof. |